INTRODUCTION: @entity3528 is highly prevalent in kidney transplant recipients, and commonly results in hypercalcaemia; an association to @entity2331 and @entity174 has also been observed. @entity21453 has proved effective to control secondary @entity740 in both dialysed and non-dialysed @entity1 , with a low hypercalcaemia incidence. Currently available experience on @entity21453 use in kidney transplant recipients is scarce. Our main aim was to show the effect of @entity21453 on mineral bone metabolism in kidney transplant recipients with @entity3528 . MATERIAL AND METHODS: A retrospective multicentre study in kidney transplant recipients aged>18 years with a 12-month or longer post-transplantation course, stable renal function, having received @entity21453 for more than 12 months, with available clinical follow-up for a 24-month period. RESULTS: A total of 69 @entity1 with a 120     92-month post-transplantation course were included. Baseline @entity1011 was 2.2  0.9mg/dl y GFR-MDRD was 36  20ml/min/1.73m(2). @entity21453 doses were gradually increased during the study: baseline 3.8  1.9 g/week, 12 months 5.2  2.4 g/week; 24 months 6.0  2.9 g/week (P<.001). Serum @entity461 levels showed a significant fast decline: baseline 288  152 pg/ml; 6  months 226  184 pg/ml; 12 months 207  120; 24 months 193  119 pg/ml (P<.001). Reduction from baseline @entity461 was >= 30% in 42.4% of @entity1 at 12 months y in 65.2% of @entity1 at 24 months. Alkaline phosphatase showed a significant decrease in first 6 months followed by a plateau: baseline 92  50 IU/l; 6  months 85  36 IU/l, 12 months 81  39 IU/l (P<.001). Overall, no changes were observed in serum @entity460 and @entity3151 , and in urine @entity460 excretion. @entity461 decline was larger in @entity1 with higher baseline levels. @entity1 with lower baseline @entity460 levels showed significantly increased levels (mean increase was 0.5-0.6mg/dl) but still within normal range, whereas @entity1 with baseline @entity460 >10mg/dl showed gradually decreasing levels. Fifteen (21.7%) @entity1 had received prior @entity3873 therapy. When shifted to @entity21453 , such @entity1 required @entity21453 doses significantly larger than those not having received @entity3873 . @entity21453 was used concomitantly to @entity4046 in 11 @entity1 with significant @entity461 reductions being achieved; clinical course was similar to other @entity1 and @entity21453 doses were also similar. CONCLUSIONS: @entity21453 is an effective therapy for @entity3528 in kidney transplant recipients. Overall, no significant changes were observed in @entity460 and @entity3151 levels or urinary excretion. @entity1 having previously received @entity3873 required higher @entity21453 doses. When used in @entity1 receiving @entity4046 , @entity21453 results in a significant @entity461 fall, with @entity21453 doses being similar to those used in @entity1 not receiving @entity4046 .

Effect of @entity21453 on mineral bone metabolism in kidney transplant recipients with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity174 :: ('MESH:D050723', 'Disease') :: ['bone fractures'] @entity3873 :: ('MESH:D002117', 'Chemical') :: ['calcitriol'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['Secondary hyperparathyroidism', 'secondary hyperparathyroidism'] @entity740 :: ('MESH:D051436', 'Disease') :: ['hyperparathyroidism in chronic kidney disease'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia'] @entity21453 :: ('MESH:C084656', 'Chemical') :: ['Paricalcitol', 'paricalcitol'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity4046 :: ('MESH:C476217', 'Chemical') :: ['cinacalcet'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus'] @entity461 :: ('5741', 'Gene') :: ['PTH']
@entity3528 :: (MESH:D006962,Disease) :: ['secondary hyperparathyroidism']
